Direct and Indirect Effects of GLP-1 and GIP Receptor Agonism in the Human Body 2,4,5,12 In addition to their beneficial actions in diabetes and obesity, new research suggests that incretin-based therapies may reduce inflammation in the heart, liver, kidneys, and brain
Protects Gastric Mucosa: It provides a cytoprotective effect, shielding the stomach lining from the damaging effects of alcohol and NSAIDs
These results indicate that rifabutin-based therapies have potential as a first- or second-line empirical treatment for H
10.1074/jbc.m114.627521 J
Biologic Exclusivity under the BPCIA, as noted, provides 12 years from the date of approval for reference products, plus a four-year data exclusivity period during which no biosimilar application can be submitted [29]
And of course, skin is a physical barrier, right